GEN Exclusives

More »

GEN News Highlights

More »
Jul 25, 2013

Oxford Pharmascience Wins Option for 53 More UCL Compounds

  • Oxford Pharmascience has entered a new agreement with University College London (UCL) giving it an option over an additional 53 compounds it could commercialize using the university's Phloral technology.

    The new deal allows Oxford Pharma through March to investigate the potential for the 53 compounds with an option to work for another year on those that have the best commercial and clinical potential.

    The agreement is an extension of a collaboration between the drug delivery company, which specializes in making drugs easier to take, and UCL, which is aimed at developing reformulations of generic statins atorvastatin and simvastatin to reduce their side effects. In September, Oxford Pharma acquired an exclusive global license for a colonic drug delivery technology for statins from UCL with the aim of developing and commercializing a range of reformulated statins using atorvastatin and simvastatin and launching a range of products under its SafeStat development program.

    "There are many other drugs widely used where side effects reduce the tolerance or compliance in patients," Nigel Theobald, Oxford Pharma’s CEO, said. "This option allows us to explore a range of potential drug candidates [that] fit with this strategy without taking our eyes off the existing programs."

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »